Shots:

• The first patient has been dosed in a P-II study of TD-0903. The P-II study consists of two parts: the first part will assess the safety- tolerability- and clinical response to treatment in sequential ascending dose cohorts of hospitalized COVID-19 patients- with each patient demonstrating hypoxia being dosed for 7 days
• The second part will be conducted at hospital-based clinical sites in the UK- EU & the US- pending appropriate Ethics Committee- and regulatory approvals in territories. The P-II study in the UK follows the completion of dosing in the P-I study in healthy volunteers
• TD-0903 is a lung-selective- nebulized pan-JAK inhibitor- being developed to treat hospitalized patients with ALI caused by COVID-19

Click here to read full press release/ article | Ref: Theravance | Image: Theravance